Carregant...
Designing and overproducing a tandem epitope of gp350/220 that shows a potential to become an EBV vaccine
BACKGROUND: Epstein-Barr virus (EBV) can cause cancer in people from around the world. There is no EBV vaccine available for use on a global scale. However, emerging evidence suggests that the epitope on the gp350/220 capsid protein may be developed into an EBV vaccine. Nevertheless, the production...
Guardat en:
| Publicat a: | Heliyon |
|---|---|
| Autors principals: | , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Elsevier
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5857718/ https://ncbi.nlm.nih.gov/pubmed/29560474 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.heliyon.2018.e00564 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|